Table 1.

Antitumor marine natural compounds in clinical trials with preclinical toxicity evaluation in animals.

Compound	Phase of clinical trails	Animal model	Toxicities
Bryostatin-1	II	Mice	In mice, toxicities include lethargy, unsteadiness,
			haematuria, and myelosuppression [8].
Dolastatin-10	II	Mice, rats, dogs	Maximum tolerated doses of 1350 μg/m2 (mice),
			450 μg/m2 (rats), and ∼ 400 μg/m2 (dogs); Myelotoxicity
			was the most severe dose-limiting effect [9].
LU103793a	II	N/A	Toxic effects in hematopoietic, lymphoid
			systems, gastrointestinal tract, and heart [8].
Discodermolidea	I	Mice	Immunosuppresive [10].
Yondelis	II/III	Mice, rats, monkeys	Reversible hepatobiliary toxicity in monkeys [11].
			Hematotoxic at MTD 600 μg/m2 in mice [12].
			Hepatotoxic in rats [13].
Squalamine	II	Monkeys	Systemic squalamine injection inhibited the
			development of iris neovascularization and caused partial
			regression of new vessels in a primate model [14]
Kahalalide F	I	Rats	MTD is 1800 μg/m2; no-adverse-effect dose
			is 480 μg/m2/day; nephrotoxic and neurotoxic [15].
Aplidin	II	Mice	More toxic effects with prolonged exposure [8].
KRN7000b	I	N/A	N/A [4, 8]
Cryptophycin-52	II	N/A	N/A [8]
Epothilone B	II	N/A	N/A [16]
LAF389c	I	N/A	N/A [4, 16]
ILX651a	I	N/A	N/A [4]
HTI286	I	N/A	N/A [4, 17]

N/A = not available.

^aDolastatin-15 analogue.

^bAgelasphin analouge (alpha-galactosylceramide).

^cBengamide B analouge.